Valneva (NASDAQ:VALN) Stock Price Up 3.9% – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) traded up 3.9% during trading on Wednesday. The company traded as high as $5.73 and last traded at $5.7780. 2,831 shares traded hands during trading, a decline of 95% from the average daily volume of 61,432 shares. The stock had previously closed at $5.56.

Analyst Upgrades and Downgrades

Several research firms have commented on VALN. TD Cowen assumed coverage on shares of Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a report on Monday, September 14th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $9.30.

Valneva Price Performance

The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. The company has a market capitalization of $540.40 million, a P/E ratio of -2.72 and a beta of 1.53. The business’s 50-day moving average price is $6.32 and its 200 day moving average price is $5.83.

Valneva (NASDAQ:VALN) last issued its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The firm had revenue of $39.37 million during the quarter, compared to the consensus estimate of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. Analysts anticipate that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.